What do you think of TTNP Probuphine Implant ? Titan Pharmaceuticals Announces Journal of the American Medical Association Publication of Phase 3 Probuphine(TM) Data SOUTH SAN FRANCISCO, Calif., Oct. 12 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (OTC Bulletin Board: TTNP) today announced that data from its previously completed and announced Phase 3 randomized, placebo-controlled clinical trial of Probuphine were published in the Journal of the American Medical Association (JAMA). The article highlights data from the 163-patient trial, which showed that patients receiving Titan's Probuphine implant had significantly less illicit opioid use, experienced fewer symptoms of withdrawal and craving, stayed in treatment longer and had greater overall improvement when compared to placebo patients over the course of the 24-week study.
Having a family member going through opiate addiction for years after a spinal injury and watching the attempts to quit using Oxy, the most key thing I see in treatment is NOT RELAPSING. He has gotten off of it several times okay but staying off of it is the challenge. Therefore, I find the opiate receptor blocking tatic ALKS is utilizing to be the most promising as a relapse would not induce intoxication and therefore be a pointless pursuit. The other aspect I like is that it is a once monthly injection - a big problem for addicts is properly taking consistently medications of any kind so any daily treatment prescription is doomed to fail as they will not take the pills. Further, the existing opiate-based treatments only continue to keep the addiction going. I am so encouraged by ALKS approach that I bought the stock for that reason...until/unless you have personally witnessed opiate dependency like I have you cannot fathom what a huge solution this may actually be.
Good points...now imagine that TTNP's probuphine only needs a visit every 6 MONTHS to your clinician and the active compound in their implant is the same with what's currently best in the market: suboxone (but it eliminates the major drawbacks it has). Do your DD..you'll be surprised how undervalued it is.
TTNP.OB is the real winner here but many did not discover it. They are conducting a phase 3 confirmatory trial now for probuphine (a six-month implant). Results are expected in Q2 2011. They also get 8-10% royalties from global Fanapt sales (a 15 billion anti-psychotic market, a drug launched this year by NOVARTIS). Visit TTNP's board to find out more about its potential.